Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
SEC filings, financial facts, source resources, and Goglides workspace context for Agilent Technologies, Inc..
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
AgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.
OpenAgilent's CrossLab segment is becoming the quiet efficiency layer for regulated pharma labs: services, consumables, software, automation, and asset monitoring. The proof gate is whether CrossLab can keep growing while margin stays strong.
OpenAgilent's CrossLab mix and cash generation point to a durable lab-workflow franchise, but the open question is whether service and consumables strength can outrun instrument-cycle volatility.
OpenTag facets appear after tag usage counts are rebuilt.